Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics

American Journal of Hypertension

Volumn 19, Issue 2, 2006, Pages 208-213

  Rayner, Brian L ^a   Trinder, Yvonne A ^a   Baines, Donette ^a   Isaacs, Sedick ^a   Opie, Lionel H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Candesartan; Fibrinogen; Hyperuricemia; Losartan; Renal function

Indexed keywords

CANDESARTAN; CREATININE; DIURETIC AGENT; FIBRINOGEN; LOSARTAN; URIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; DIURETICS; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; HYPERURICEMIA; LOSARTAN; MALE; TETRAZOLES; TREATMENT OUTCOME; URIC ACID;

EID: 33644815752     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.08.005     Document Type: Article

References (32)

1. J.V. Selby, G.D. Friedman, C.P. Queensbury Precursors of essential hypertension pulmonary function, heart rate, uric acid, serum cholesterol and other chemistries Am J Epidemiol 131 1990 1017 1027
2. A. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr, E.J. Roccella Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. J Am Med Assoc 289 2003 2560 2582
3. Treatment of Mild Hypertension Research Group Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies Ann Intern Med 151 1991 1413 1423
4. B.A. Soffer, J.T. Wright, J.H. Pratt, B. Wiens, A.I. Goldberg, C.S. Sweet Effects of losartan on a background of hydrochlorothiazide in patients with hypertension Hypertension 26 1995 112 117
5. J. Fang, M.H. Alderman Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey J Am Med Assoc 283 2000 2404 2410
6. P.E. Puddu, M. Lanti, A. Menotti, M. Mancini, A. Zanchetti, M. Cirillo, M. Angeletti, W. Panerelli Gubbio Study Research Group Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population study Acta Cardiol 56 2001 243 251
7. D.I. Feig, R.J. Johnson Hyperuricemia in childhood primary hypertension Hypertension 42 2003 247 252
8. K. Sakata, T. Hashimoto, H. Ueshima, A. Okayama NIPPON DATA 80 Research Group Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-11994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged Eur J Epidemiol 17 2001 461 468
9. J.T. Moriarity, A.R. Folsom, C. Iribarren, F.J. Nieto, W.D. Rosamond Serum uric acid and risk of coronary heart disease Atherosclerosis Risk in Communities (ARIC) Study Ann Epidemiol 10 2000 136 143
10. A.J. Reyes, W.P. Leary The increase in serum uric acid induced by diuretics could be beneficial to cardiovascular prognosis in hypertension a hypothesis J Hypertens 21 2003 1775 1777
11. D.H. Kang, T. Nakagawa, L. Feng, S. Watanabe, L. Han, M. Mazzali, L. Truong, R. Harris, R.J. Johnson A role for uric acid in the progression of renal disease J Am Soc Nephrol 13 2002 2888 2897
12. L. Beck Requiem for gouty nephropathy Kidney Int 30 1986 280 287
13. J. Syrijänen, J. Mustonen, A. Pasternak Hypertriglyceridemia and hyperuricaemia are risk factors for progression of IgA nephropathy Nephrol Dial Transplant 15 2000 34 42
14. I. Ohno, T. Hosoya, H. Gomi, K. Ichida, H. Okabe, M. Hikita Serum uric acid and renal prognosis in IgA nephropathy Nephron 87 2001 333 339
15. S. Bo, P. Cavallo-Perin, R. Gentile, E. Repetti, G. Pagano Hypouricemia and hyperuricaemia in type 2 diabetes two different phenotypes Eur J Clin Invest 31 2001 318 321
16. T.R. Srinivas, J. Herrera-Acosta, D.I. Feig, D.-H. Kang, M.S. Segal, R.I. Johnson Diuretic-induced hyperuricaemia does not decrease cardiovascular risk J Hypertens 22 2004 1415 1417
17. A.J. Reyes, W.P. Leary Diuretic-induced hyperuricaemia does not decrease cardiovascular risk. Reply J Hypertens 22 2004 1417 1419
18. W.B. Kannel, P.A. Wolf, W.P. Castelli, R.B. D'Agostino Fibrinogen and risk of cardiovascular disease. The Framingham Study J Am Med Assoc 258 1987 1183 1186
19. S.C. Kofoed, H.H. Wittrup, H. Silleson, B.G. Nordestgaard Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques. The Copenhagen City Heart Study Eur Heart J 24 2003 567 576
20. F. Schmitt, S. Natov, F. Martinez, B. Lacour, T. Hannedouche Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man Clin Sci 90 1996 205 213
21. L.V. Franse, M. Pahor, M. Di Bari, R.I. Shorr, J.Y. Wan, G.W. Somes, W.B. Applegate Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP) J Hypertens 18 2000 1149 1154
22. A. Hoieggen, M.H. Alderman, S.E. Kjeldsen, S. Julius, R.B. Devereux, U. De Faire, F. Fyhrquist, H. Ibsen, K. Kristianson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, C. Chen, B. Dahlof LIFE Study Group The impact of serum uric acid on cardiovascular outcomes in the LIFE study Kidney Int 65 2004 1041 1049
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic J Am Med Assoc 288 2002 2981 2997
24. M. Laposata SI Unit Conversion Guide NEJM Books 1992, Boston
25. R. Fogari, A. Zoppi, G.D. Malamani, G. Marasi, A. Vanasia, G. Villa Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients Br J Clin Pharmacol 39 1995 616 620
26. R. Fogari, A. Zoppi, P. Lazzari, P. Preti, A. Mugellini, L. Corradi, P. Lusardi ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients J Cardiovasc Pharmacol 32 1998 616 620
27. T.K. Makris, G.A. Stavroulakis, P.G. Krespi, A.N. Hatzizacharias, F.K. Triposkiadis, C.G. Tsoukala, V.V. Votteas, M.K. Kyriakidis Fibrinolytic/ hemostatic variables in arterial hypertension response to treatment with irbesartan or atenolol Am J Hypertens 13 2000 783 788
28. J. Bhatia, P. Mahajan, M. Sikka, O.P. Kalra Effect of various antihypertensive therapies on plasma fibrinogen levels in patients with essential hypertension Indian J Med Sci 55 2001 491 494
29. H. Lithell, L. Hansson, I. Skoog, D. Elmfeldt, A. Hofman, B. Olofsson, P. Trenkwalder, A. Zanchetti SCOPE Study Group The study on cognition and prognosis in the elderly (SCOPE) principal results of a randomized double-blind intervention trial J Hypertens 21 2003 875 886
30. L.H. Lindholm, H. Ibsen, B. Dahlöf, R.B. Devereux, G. Beevers, U. de Faire, F. Fyhrquist, S. Julius, S.E. Kjeldsen, K. Kristiansson, O. Lederballe-Pedersen, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, P. Aurup, J. Edelman, S. Snapinn LIFE Study Group Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE) Lancet 359 2002 1004 1010
31. J. Schrader, S. Luders, A. Kulschewski, F. Hammersen, K. Plate, J. Berger, W. Zidek, P. Dominiak, H.C. Diener MOSES Study Group Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention Principal Results of a Prospective Randomized Controlled Study (MOSES) Stroke 36 2005 1218 1226
32. R.G. Hawkins, M.C. Houston Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? Am J Hypertens 18 2005 744 749